1-2 of 2
Peiqiong Lai
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Acalabrutinib in Chinese Patients (Pts) with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): 12-Month Efficacy and Safety Results from an Open-Label, Multicenter Phase 1/2 Trial

Shenmiao Yang, Haiwen Huang, Keshu Zhou, Xielan Zhao, Yanqiu Han, Lindong Li, Anna Butturini, Yujie Wang, Xiaofeng Liu, Peiqiong Lai, Jianyong Li
Journal: Blood
Blood (2023) 142 (Supplement 1): 6537.
https://doi.org/10.1182/blood-2023-173399
Published: 2023
Journal Articles

Pharmacokinetics, Safety, and Efficacy of Acalabrutinib in Chinese Patients with Relapsed/Refractory Mantle Cell Lymphoma and Other B-Cell Malignancies: An Open-Label, Multicenter Phase 1/2 Trial

Jun Zhu, Yuqin Song, Jianyong Li, Keshu Zhou, Xiaoyan Ke, Zhen Cai, Huilai Zhang, Tingting Yao, Zhen Xia, Yiqiu Wang, Peiqiong Lai, Xiaofeng Liu
Journal: Blood
Blood (2022) 140 (Supplement 1): 6496–6497.
https://doi.org/10.1182/blood-2022-157057
Published: 2022